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Chronic lymphocytic leukemia (CLL) is the most common human leukemia, accounting for ~10,000 new cases diagnosed each year in the United States (~30% of all leukemia cases) [1] . CLL is mostly a disease of elderly people, with the incidence increasing linearly with each decade [1, 2] . This disease occurs in two forms, aggressive and indolent, both forms are is characterized by the clonal expansion of CD5 positive B-cells [1, 2] . Aggressive CLL is characterized by high ZAP-70 expression and unmutated IgH V H ; indolent CLL shows low ZAP-70 expression and mutated IgH V H [1, 2] .
MicroRNAs are endogenous non-coding RNAs 19-25 nucleotides in size [3] . Recent studies have shown that microRNAs play important roles in various cellular processes including DNA methylation [4] , cellular growth, differentiation and apoptosis [5] . Recent studies revealed that nearly half of human microRNAs are located within fragile sites and genomic regions altered in various cancers [6] . Numerous reports demonstrated that, as protein coding genes, microRNAs differentially express in a number of cancers, indicating that individual microRNAs could play tumor suppressor or oncogenenic roles in cancer pathogenesis [7] .
Several recent studies demonstrated that microRNA expression profiles can be used to distinguish normal B-cells from malignant CLL cells and that microRNA signatures are associated with prognosis and progression of CLL [6, 8] . Specifically, a signature profile was reported, describing 13 microRNAs that differentiate aggressive and indolent CLL [6] .
Tcl1 is a critical molecule in the pathogenesis of CLL [9] . Mouse model studies conclusively demonstrated that deregulation of TCL1 is initiating event in the development of the aggressive form of CLL [10, 11] , in fact recent studies showed that Tcl1-driven mouse CLL closely resembles the aggressive form of human B-CLL and the analysis for V H mutations showed that all the CLLs in transgenic mice carried unmutated V H genes in accordance with the aggressive phenotype [12] . We, and others, reported that the aggressive form of human B-CLL shows the highest Tcl1 expression levels [13, 14] . Several years ago we investigated whether microRNAs regulate TCL1 expression in CLL. We demonstrated that miR-29 and miR-181 target TCL1 expression in CLL [14] .
Interestingly, of the four down-regulated microRNAs in aggressive CLL versus indolent B-CLL, three are different isoforms of miR-29 (miR-29a-2, miR-29b-2 and miR-29c) [6] , strongly suggesting that miR-29 and TCL1 interactions play an important role in the pathogenesis of aggressive CLL [14] . The fact that miR-29 targets expression of TCL1, a critical oncogene in aggressive CLL, indicates that miR-29 might function as a tumor suppressor in CLL.
As noted above, we have previously reported that miR-29 expression is down-regulated in aggressive versus indolent CLL [8, 14] , but these reports did not examine miR-29 expression in CLL versus normal CD19+ B-cells. In our latest publication in PNAS we examined expression of miR-29a and miR-29b in 29 aggressive CLL samples, 33 indolent CLL samples and two normal CD19+ B-cell controls [15] . We found that miR-29a and miR-29b expression was 4-4.5 fold higher in indolent CLL, when compared with normal CD19+ B-cells [15] . Table 1 (85%) miR-29 transgenic mice; ~50% of B-cells in these transgenics were CD5 positive [15] . These data confirmed our initial observations that miR-29 transgenic mice develop disease that mimics indolent human CLL.
Previously we reported that miR-29 is one of two microRNAs targeting TCL1, a very important oncogene involved in the pathogenesis of aggressive CLL [14] . We also showed that TCL1 and miR-29 expression levels are inversely correlated in CLL, and that miR-29 expression is down-regulated in aggressive CLL versus indolent CLL [14] . These data suggest possible tumor suppressor function for miR-29 in CLL. Very recently we reported that miR-29 is up-regulated in indolent CLL compared to normal B-cells [15] . We also found that miR-29 transgenic mice showed expanded CD5+CD19+IgM+ B-cell populations and develop a disease very similar to indolent human CLL [15] . This implies that up-regulation of miR-29 initiates or at least significantly contributes to the pathogenesis of indolent CLL and can function as an oncogene. How can we reconcile these differences? Figure 1 shows our current view of the function of miR-29 in CLL. Since TCL1 is mostly not expressed in indolent CLL [14] , it likely does not play an important role in indolent CLL. Thus its down-regulation due to miR-29 overexpression does not slow indolent CLL development. We believe that up-regulation of miR-29 expression is not sufficient to cause aggressive CLL. In contrast, up-regulation of Tcl1 is absolutely required for the initiation of the aggressive form of CLL. In the other hand, down-regulation of miR-29 expression in aggressive CLL (compared to the indolent form) contributes to up-regulation of Tcl1 and development of aggressive CLL.
Since in all human B-CLL samples miR-29a expression levels were >20-fold higher compared to miR-29b [15] and both microRNAs share the same seed sequence, it is likely that most of effects of expression of miR-29ab cluster in CLL can be attributed to miR-29a. MiR-29 functions as an oncogene in B-cells by regulating its targets.
Targetscan software predicts over 800 targets for miR-29. This list contains multiple oncogenes and tumor suppressor genes. Previous reports showed that miR-29 can target TCL1, MCL1 and CDK6 oncogenes [14, 17, 18] ; we propose that miR-29 targets possible tumor suppressor peroxidasin [15] . Clearly, interactions of miR-29 with these genes contribute to its function, but it is very likely that hundreds of unknown interactions of miR-29 with its targets hold keys to its oncogenic role in CLL.
MicroRNA expression profiles were extensively studied in a number of hematological malignancies as well as in solid tumors [7] . These studies resulted in identification of several microRNAs that might function as tumor suppressors or oncogenes [7] . However, there have been only two reports demonstrating that dysregulation of a single microRNA (or a cluster) can cause cancer. The first such study defined an initiation role of miR-155 in B-cell acute leukemias [19] . Another study demonstrated that knockout of miR-15/16 led to the development of indolent B-cell malignancies [20, 21] . In both cases previously published reports identified miR-155 as an oncogene and miR-15/16 as a tumor suppressor. In contrast, there has not been a clear consensus regarding the function of miR-29 in this respect. Previous studies showed that miR-29 expression was down-regulated and correlated with poor prognosis in mantle cell lymphoma [22] , its re-expression caused apoptosis AML cells [17] and suppressed tumorigenicity in lung cancer cells [23] . On the other hand, in addition to our report [15] , dysregulation of miR-29 expression in myeloid cells was found to cause AML in a mouse model [24] , and its overexpression was reported in metastatic breast cancer [25] . Thus, it is apparent that depending on cellular contexts miR-29 can function as an oncogene or a tumor suppressor.
